

**Supplementary Table 1.** Prescription status of triple combination of OHAs in study population at baseline

Triple combinations ( <i>n</i> =357)			No. (%)
Metformin	Sulfonylurea or glinide	DPP4 inhibitor	239 (66.9)
		Thiazolidinedione	39 (10.9)
		$\alpha$ -Glucosidase inhibitor	16 (4.5)
		SGLT2 inhibitor	13 (3.6)
	DPP4 inhibitor	Thiazolidinedione	29 (8.1)
		SGLT2 inhibitor	9 (2.5)
		Thiazolidinedione	2 (0.6)
Sulfonylurea or glinide	Thiazolidinedione	DPP4 inhibitor	6 (1.7)
		SGLT2 inhibitor	1 (0.3)
	DPP4 inhibitor	$\alpha$ -Glucosidase inhibitor	2 (0.6)
		SGLT2 inhibitor	1 (0.3)

OHA, oral hypoglycemic agent; DPP4, dipeptidyl peptidase 4; SGLT2, sodium-glucose cotransporter 2.